HCV INFECTION AND DIABETES MELLITUS. LITERATURE REVIEW.
Introduction. Hepatitis C virus (HCV) and diabetes mellitus (DM) are among the major public health problems that are a heavy burden on health and costly around the world [21,44,62,70]. HCV infection causes liver manifestations such as hepatitis, cirrhosis, and hepatocellular carcinoma, and is also involved in the pathogenesis of extrahepatic manifestations, including metabolic disorders such as diabetes. Multiple longitudinal and cross-sectional studies have shown a higher incidence and prevalence of hyperglycemia in HCV seropositive than in controls without HCV infection. [41,55].
The diabetogenic potential of the liver has long been known, and in 1906 [38] the name "hepatogenic diabetes" (HD) was proposed to define this condition. Currently, DM2 and HD are treated similarly because there are no standardized recommendations. Various pathophysiological underpinnings of HD may influence treatment options. One review article discusses the existence of HD as a distinct disease with high prevalence rates, a strong pathophysiological basis, clinical and therapeutic implications, and widespread skepticism and knowledge gaps. However, it is still an underestimated problem and scientific organizations do not recognize it as a separate type of diabetes. [2]
Aim: to summarize the literature on the comorbidity of type 2 diabetes mellitus and viral hepatitis C.
Search strategy. We have conducted an analytical review of open access sources from scientific databases Scopus, PubMed, Google Scholar, Web of Science, e-library over the past 20 years (2003-2023). Key words were used for the search: diabetes mellitus, hepatogenic diabetes, HCV infection, viral hepatitis C, incretins, insulin resistance, NAFLD. The publications included in the literature review were full-text articles in Russian and English. A total of 143 were analyzed, of which 70 met the study objectives and inclusion criteria.
Results. The review material presents possible pathogenetic mechanisms of the influence of HCV infection on the development and course of diabetes mellitus.
Conclusion. Based on the literature review, it was found that the main task for carrying out measures for the prevention, early detection and reduction of the risk of developing complications in diabetes mellitus and viral hepatitis C is a combination of educational, preventive, screening and therapeutic work.
Keywords: diabetes mellitus, hepatogenic diabetes, HCV infection, viral hepatitis C, incretins, insulin resistance, NAFLD.
Manzura S. Baimukhanova1, https://orcid.org/0000-0001-6040-4187
Gaukhar M. Kurmanova2, https://orcid.org/0000-0002-5768-0209
Zhanay A. Akanov3, https://orcid.org/0000-0002-9682-5941
1. Министерство здравоохранения Республики Казахстан. Электронный регистр диспансерных больных. https://www.eisz.kz/логин. (Дата обращения: 15.06.2023).
2. Adeva-Andany M.M., Pérez-Felpete N., Fernández-Fernández C., Donapetry-García C., Pazos-García C. Liver glucose metabolism in humans. Bioscience reports, 2016. 36(6), e00416. https://doi.org/10.1042/BSR20160385.
3. Adinolfi L.E., Petta S., Fracanzani A.L., Coppola C., Narciso V., Nevola R., Rinaldi L., Calvaruso V., Staiano L., Di Marco V., et al. Monitoring hepatitis C virus clearance with antiviral treatment to directly influence the incidence of major cardiovascular events: a prospective multicenter study. Atherosclerosis. 2020. 296: 40–47. doi: 0.1016/j.atherosclerosis.2020.01.010. [PubMed] [ CrossRef]
4. Adinolfi L.E., Nevola R., Guerrera B., D'Alterio G., Marrone A., Giordano M., Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. Journal of gastroenterology and hepatology, 2018. 33(7), 1379–1382. https://doi.org/10.1111/jgh.14067.
5. Alzahrani N. Hepatitis C virus, insulin resistance, and diabetes: A review. Microbiology and immunology, 2022. 66(10), 453–459. https://doi.org/10.1111/1348-0421.13023.
6. Antonelli, A., Ferri C., Fallahi P., et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes care, 2005. 28(10), 2548–2550. https://doi.org/10.2337/diacare.28.10.2548.
7. Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes. 2014 Oct 15;5(5):586-600. doi: 10.4239/wjd.v5.i5.586. PMID: 25317237; PMCID: PMC4138583.
8. Armandi A., Rosso C., Caviglia G.P., Bugianesi E. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites, 2021. 11(3), 155. https://doi.org/10.3390/metabo11030155.
9. Aytug S., Reich D., Sapiro L.E., Bernstein D., Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology (Baltimore, Md.), 2003. 38(6), 1384–1392. https://doi.org/10.1016/j.hep.2003.09.012.
10. Butt A.A., Yan P., Aslam S., Shaikh O.S., Abou-Samra A.B. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. 70(6), 1153–1160. https://doi.org/10.1093/cid/ciz304.
11. Candido R., Gaiotti S., Giudici F., Toffoli B., De Luca F., Velardi V., Petrucco A., Gottardi C., Manca E., Buda I., Fabris B., Bernardi S. Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes. Journal of clinical medicine, 12(18), 6052. https://doi.org/10.3390/jcm12186052.
12. Castera L., Cusi K. Diabetes and cirrhosis: Current concepts on diagnosis and management. Hepatology (Baltimore, Md.), 2023. 77(6), 2128–2146. https://doi.org/10.1097/HEP.0000000000000263.
13. Chen L.K., Chou Y.C., Tsai S.T., Hwang S.J., Lee S.D. Type 1 diabetes mellitus associated with hepatitis C viral infection. Diabetes. 2005. 22: 340–343. doi: 10.1111/j.1464-5491.2005.01412.x.[PubMed] [CrossRef] [Академия Google].
14. Chevaliez S., Pawlotsky J.M. HCV Genome and Life Cycle. In S.L. Tan (Ed.), Hepatitis C Viruses: Genomes and Molecular Biology. Horizon Bioscience. 2006. Chapter 1.
15. Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8:332–42. doi: 10.1016/S2468-1253(22)00386-7.
16. De Oliveira Dos Santos A.R., de Oliveira Zanuso B., Miola V.F.B., Barbalho S.M., Santos Bueno P.C., et al. Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions. International journal of molecular sciences, 2021. 22(5), 2639. https://doi.org/10.3390/ijms22052639.
17. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 2006. 368 (9548), 1696–1705. https://doi.org/10.1016/S0140-6736(06)69705-5.
18. D'Souza R., Sabin C.A., Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. The American journal of gastroenterology, 2005. 100(7), 1509–1515. https://doi.org/10.1111/j.1572-0241.2005.41403.x.
19. Easterbrook P., Luhmann N., Newman M., Walsh N., Lesi O., Doherty M. New WHO guidance for country validation of viral hepatitis B and C elimination. The lancet. Gastroenterology & hepatology. 2021. 6(10), 778–780.https://doi.org/10.1016/S2468-1253(21)00267-3
20. Elkrief L., Rautou P.E., Sarin S., Valla D., Paradis V., Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver international: official journal of the International Association for the Study of the Liver, 2016. 36(7), 936–948. https://doi.org/10.1111/liv.13115.
21. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The lancet. Gastroenterology & hepatology, 2017. 2(5), 325–336. https://doi.org/10.1016/S2468-1253(17)30045-6.
22. Garcia-Compean D., Jaquez-Quintana J.O., Gonzalez-Gonzalez J.A., Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World journal of gastroenterology, 2009. 15(3), 280–288. https://doi.org/10.3748/wjg.15.280.
23. Giordanino C., Bugianesi E., Smedile A., Ciancio A., Abate M.L., et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. The American journal of gastroenterology, 2008. 103(10), 2481–2487. https://doi.org/10.1111/j.1572-0241.2008.02002.x.
24. Gonzalez-Gil A.M., Elizondo-Montemayor L. The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review. Nutrients, 2020. 12(6), 1899. https://doi.org/10.3390/nu12061899.
25. Grancini V., Trombetta M., Lunati M.E., Boselli M.L , Gatti S., Donato M.F., Palmieri E., Resi V., Pugliese G., Bonadonna R.C., Orsi E. Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients. J Hepatol. 2019. 70:954-62. PMID:30677460 DOI:10.1016/j.jhep.2019.01.015
26. Hammerstad S.S., Blackard J.T., Lombardi A., Owen R.P., Concepcion E., Yi Z., Zhang W., Tomer Y. Hepatitis C Virus Infection of Human Thyrocytes: Metabolic, Hormonal, and Immunological Implications. The Journal of clinical endocrinology and metabolism, 2020. 105(4), 1157–1168. https://doi.org/10.1210/clinem/dgz241
27. Harrison S.A. Liver disease in patients with diabetes mellitus. Journal of clinical gastroenterology, 2006. 40(1), 68–76. https://doi.org/10.1097/01.mcg.0000190774.91875.d2.
28. Hickman I.J., Macdonald G.A. Impact of diabetes on the severity of liver disease. The American journal of medicine, 2007. 120(10), 829–834.
29. Hliwa A., Ramos-Molina B., Laski D., Mika A., Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. International journal of molecular sciences, 2021. 22(13), 6900. https://doi.org/10.3390/ijms22136900.
30. Holstein A., Hinze S., Thiessen E., Plaschke A., Egberts E.H. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of gastroenterology and hepatology, 2002. 17(6), 677–681. https://doi.org/10.1046/j.1440-1746.2002.02755.
31. Hu H., Hu X., Tian C., Zhu Y., et al. Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-associated acute-on-chronic liver failure. Hepatol Int. 2021. [PMID:34373965 DOI:10.1007/s12072-021-10243-1].
32. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., McCaughan G.W., George J. Insulin resistance is associated with chronic hepatitis C virus infection and progression of fibrosis. Gastroenterology. 2003. 125: 1695–1704. [PubMed]. [Академия Google].
33. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3. PMID: 28922704; PMCID: PMC6484376.
34. Jumabayeva A., Nersesov A., Kulzhanov M., Nefedova M., Nuraliyeva G., Rakhimbekova G., Tanabayeva S., Fakhradiyev I. Prevalence of Viral Hepatitis B, C, and D in Kazakhstan. The Scientific World Journal, 2022, 9102565. https://doi.org/10.1155/2022/9102565
35. Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020. 10:107-111. [PMID:32175717 DOI:10.2991/jegh.k.191028.001]
36. Konishi I., Hiasa Y., Shigematsu S., Hirooka M., Furukawa S., Abe M., Matsuura B., Michitaka K., Horiike N., Onji M. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver international: official journal of the International Association for the Study of the Liver, 2009. 29(8), 1194–1201. https://doi.org/10.1111/j.1478-3231.2009.02043.
37. Kucukoglu O., Sowa J.P., Mazzolini G.D., Syn W.K., Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol 2021. 74:442-57. PMID:33161047 DOI:10.1016/j.jhep.2020.10.030
38. Kumar R., García-Compeán D., Maji T. Hepatogenous diabetes: Knowledge, evidence, and skepticism. World journal of hepatology, 2022. 14(7), 1291–1306. https://doi.org/10.4254/wjh.v14.i7.1291.
39. Kuroda T., Hirooka M., Koizumi M., Ochi H., Hisano Y., Bando K., Matsuura B., Kumagi T., Hiasa Y. Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion. Journal of gastroenterology, 2015. 50(6), 683–693. https://doi.org/10.1007/s00535-014-1001-8.
40. Lecube A., Hernández C., Genescà J., Esteban J.I. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes care, 2004. 27(5), 1171–1175. https://doi.org/10.2337/diacare.27.5.1171.
41. Lee W.G., Wells C.I., McCall J.L., Murphy R., Plank L.D. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis. Diabetes Metab Res Rev 2019;35:e3157. PMID: 30901133 DOI: 10.1002/dmrr.3157
42. Lee M.H., Yang H.I., Wang C.H., et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke, 2010. 41(12), 2894–2900. https://doi.org/10.1161/STROKEAHA.110.598136.
43. Lombardi A., Mondelli M.U. ESCMID Study Group for Viral Hepatitis (ESGVH) Hepatitis C: Is eradication possible? Liver international: official journal of the International Association for the Study of the Liver, 2019. 39(3), 416–426. https://doi.org/10.1111/liv.14011.
44. Love K.M., Liu Z. DPP4 Activity, Hyperinsulinemia, and Atherosclerosis. The Journal of clinical endocrinology and metabolism, 2021. 106(6), 1553–1565. https://doi.org/10.1210/clinem/dgab078.
45. Marra F., Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. Journal of hepatology, 2018. 68(2), 280–295. https://doi.org/10.1016/j.jhep.2017.11.014
46. Mazzaro C., Quartuccio L., Adinolfi L.E., Roccatello D., Pozzato G., Nevola R., Tonizzo M., Gitto S.,et al. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses. 2021 Nov 9;13(11):2249. doi: 10.3390/v13112249.
47. McLean B.A., Wong C.K., Campbell J.E., Hodson D.J., Trapp S., Drucker D.J. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine reviews, 2021. 42(2), 101–132. https://doi.org/10.1210/endrev/bnaa032
48. Meex R.C.R., Ватт M.J. Hepatokines: the relationship between non-alcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017. 13: 509-20. [PMID:28621339 DOI:10.1038/nrendo.2017.56.
49. Nauck M.A., Müller T.D. Incretin hormones and type 2 diabetes. Diabetologia, 2023. 66(10), 1780–1795. https://doi.org/10.1007/s00125-023-05956-x .
50. Nevola R., Acierno C., Pafundi PC, Adinolfi L. Chronic hepatitis C infection causes cardiovascular disease and type 2 diabetes: mechanisms and treatment. Minerva Med.2020. 112: 118–200.
51. Nishida T., Tsuji S., Tsujii M., Arimitsu S., Haruna Y., Imano E., Suzuki M., et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006. 101:70-5. PMID:16405536 DOI:10.1111/j.1572-0241.2005.00307.x
52. Nishikawa H., Enomoto H., Ishii A., Iwata Y., Miyamoto Y., Ishii N., et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. Journal of cachexia, sarcopenia and muscle. 2017. 8(6), 915–925. https://doi.org/10.1002/jcsm.12212.
53. Orsi E., Grancini V., Menini S., Aghemo A., Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int 2017;37:950-62.
54. Perseghin G., Mazzaferro V., Sereni L.P., Regalia E., Benedini S., Bazzigaluppi E., et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology (Baltimore, Md.), 2000.31(3), 694–703. https://doi.org/10.1002/hep.510310320.
55. Qiu J., Thapaliya S., Runkana A., Yang Y., Tsien C., Mohan M.L., et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci USA. 2013;110:18162-18167.
56. Rajewski P., Zarębska-Michaluk D., Janczewska E., Gietka A., Mazur W., et al. HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study. J Clin Med. 2022 Jan 13;11(2):379. doi: 10.3390/jcm11020379.
57. Ramachandran T.M., Rajneesh A.H.R., Zacharia G.S., Adarsh R.P. Cirrhosis of Liver and Diabetes Mellitus: The Diabolic Duo? Journal of clinical and diagnostic research: JCDR, 2017. 11(9), OC01–OC05. https://doi.org/10.7860/JCDR/2017/30705.10529.
58. Revie D., Salahuddin S.Z. 2011. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virology journal, 8, 346. https://doi.org/10.1186/1743-422X-8-346.
59. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., Salmerón J., Diago M. et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. PMID: 15765399.
60. Shi J., Fan J., Su Q., Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Frontiers in endocrinology, 2019. 10, 703. https://doi.org/10.3389/fendo.2019.00703
61. Skowroński M., Zozulińska D., Juszczyk J., Wierusz-Wysocka B. Hepatitis C virus infection: evidence of an association with type 2 diabetes. Diabetes care. 2006. 29: 750.
62. Stepanova M., Younossi Z.M. Economic Burden of Hepatitis C Infection. Clinics in liver disease, 2017.21(3), 579–594. https://doi.org/10.1016/j.cld.2017.03.012
63. Svegliati-Baroni G. et al. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free radical biology medicine, 2019. 144, 293–309. https://doi.org/10.1016/j.freeradbiomed.2019.05.029 .
64. Thandassery R.B., Montano-Loza A.J. Role of Nutrition and Muscle in Cirrhosis. Current treatment options in gastroenterology, 2016. 14(2), 257–273. https://doi.org/10.1007/s11938-016-0093-z .
65. Vasepalli P., Noor M.T., Thakur B.S. Hepatogenous Diabetes - A Report from Central India. Journal of clinical and experimental hepatology, 2022. 12(2), 312–318. https://doi.org/10.1016/j.jceh.2021.08.018.
66. Wang X., Mei X., Kong D. The effect of diabetes on the incidence of rebleeding after endoscopic treatment in patients with liver cirrhosis. Expert Ter Med. 2020. 20:1299-1306. [PMID: 32742363 DOI: 10.3892/etm.2020.8876 ].
67. Yeh M.L., Huang J.F., Yu M.L., Dai C.Y., Chuang W. L. Unveiling glucose abnormalities in patients with chronic hepatitis C infection. The American journal of gastroenterology, 2009. 104(4), 1051–1052. https://doi.org/10.1038/ajg.2009.9.
68. Younossi Z.M., Otgonsuren M., Henry L., Venkatesan, C., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology (Baltimore, Md.), 2015. 62(6), 1723–1730. https://doi.org/10.1002/hep.28123.
69. Zeng H., Cao M., Xia C. et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study. Nat Cancer 4, 1382–1394 (2023). https://doi.org/10.1038/s43018-023-00618-8
70. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature, 2001. 414(6865), 782–787. https://doi.org/10.1038/414782a.
Number of Views: 169
Bibliography link
Baimukhanova M.S., Kurmanova G.M., Akanov Zh.A. HCV infection and diabetes mellitus. A review // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (3), pp. 155-163. doi 10.34689/SH.2024.26.3.018Related publications:
CHARACTERISTICS OF THE INTESTINAL MICROBIOME IN STROKE PATIENTS WITH INSULIN RESISTANCE
REACTIVE ARTHRITIS IN THE CONTEXT OF CONNECTIVE TISSUE DYSPLASIA – THE ROLE OF THE ORGANISM'S MICROBIOME
EMBOLIZATION OF THE UTERINE ARTERIES FOR LATE POSTPARTUM HEMORRHAGE DUE TO METROENDOMETRITIS: A CLINICAL CASE
DESCRIPTION OF A CLINICAL CASE OF GENERALIZED LYMPHADENOPATHY OF UNKNOWN ETIOLOGY
CLINICAL RELEVANCE OF KRAS MUTATION TESTING IN METASTATIC COLORECTAL USING DIFFERENT SEQUENCING PLATFORMS: A CASE REPORT